tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Calliditas Therapeutics (CALT), AK Medical Holdings Ltd. (HK:1789) and Consun Pharmaceutical Group Ltd. (Frankfurt: DE:C1P)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Calliditas Therapeutics (CALTResearch Report), AK Medical Holdings Ltd. (HK:1789Research Report) and Consun Pharmaceutical Group Ltd. (DE:C1PResearch Report) with bullish sentiments.

Calliditas Therapeutics (CALT)

Kepler Capital analyst Jon Berggren maintained a Buy rating on Calliditas Therapeutics on March 7 and set a price target of SEK160.00. The company’s shares closed last Thursday at $21.01.

Berggren has an average return of 9.1% when recommending Calliditas Therapeutics.

According to TipRanks.com, Berggren is ranked #7092 out of 8779 analysts.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Calliditas Therapeutics with a $36.31 average price target, which is a 72.8% upside from current levels. In a report issued on February 21, LifeSci Capital also maintained a Buy rating on the stock with a $44.00 price target.

See today’s best-performing stocks on TipRanks >>

AK Medical Holdings Ltd. (HK:1789)

In a report issued on March 28, Jill Wu from CMB International Securities maintained a Buy rating on AK Medical Holdings Ltd., with a price target of HK$7.20. The company’s shares closed last Thursday at HK$4.92.

According to TipRanks.com, Wu is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.8% and a 28.0% success rate. Wu covers the Healthcare sector, focusing on stocks such as CSPC Pharmaceutical Group, Wuxi Biologics (Cayman), and Innovent Biologics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AK Medical Holdings Ltd. with a HK$8.05 average price target, a 65.3% upside from current levels. In a report issued on March 28, Goldman Sachs also maintained a Buy rating on the stock with a HK$8.90 price target.

Consun Pharmaceutical Group Ltd. (DE:C1P)

DBS analyst Nico Chen maintained a Buy rating on Consun Pharmaceutical Group Ltd. on March 28 and set a price target of HK$7.10. The company’s shares closed yesterday at EUR0.66.

According to TipRanks.com, Chen is ranked #6044 out of 8779 analysts.

Currently, the analyst consensus on Consun Pharmaceutical Group Ltd. is a Moderate Buy with an average price target of EUR0.84.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on CALT:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles